scholarly journals Percutaneous Closure of Patent Foramen Ovale and Secundum Atrial Septal Defects with the GORE�CARDIOFORM Septal Occluder: Incidence and Implications of Device Wire Frame Fracture

2020 ◽  
Vol 15 (5) ◽  
pp. 347-360 ◽  
Author(s):  
Biagio Castaldi ◽  
Giulio Cabrelle ◽  
Massimo Padalino ◽  
Vladimiro Vida ◽  
Ornella Milanesi ◽  
...  
Keyword(s):  
Patent Foramen Ovale ◽  
Percutaneous Closure ◽  
Foramen Ovale ◽  
Septal Defects ◽  
Atrial Septal Defects ◽  
Wire Frame

scholarly journals Safety and Cost Implications of Same-Day Discharge Following Elective Percutaneous Closure of Patent Foramen Ovale and Atrial Septal Defects in Australia

Hearts ◽  
2021 ◽  
Vol 2 (4) ◽  
pp. 543-550
Author(s):  
Abhisheik Prashar ◽  
Sanjana Shah ◽  
Richard Zhang ◽  
Kurt Mitchell ◽  
Mark Sader
Keyword(s):  
Patent Foramen Ovale ◽  
Structural Heart Disease ◽  
Percutaneous Closure ◽  
Foramen Ovale ◽  
Primary Analysis ◽  
Septal Defects ◽  
Atrial Septal Defects ◽  
Same Day Discharge ◽  
Asd Closure ◽  
Cost Implications

Background: Percutaneous closure of patent foramen ovale (PFO) and atrial septal defects (ASD) is being more commonly performed due to changes in international guidelines supporting its use. This study was performed to determine the clinical outcomes, safety and cost implications of same-day discharge (SDD) following such procedures and place this in an Australian context. Methods: This was a retrospective, observational study of patients undergoing elective percutaneous PFO or ASD closure at St. George Hospital, Australia between January 2011 and January 2020. Primary outcomes included 30-day major adverse cardiovascular endpoints (MACE) and readmission to hospital within 30 days. Results: Twenty-four patients were included in the primary analysis. Ten (41.7%) patients underwent elective ASD closure while 14 (58.3%) underwent PFO closure. Among the 24 patients who underwent elective percutaneous closure of structural heart disease, 23 patients (95.8%) were managed with SDD. There were no MACE outcomes at 30 days. No patients were re-admitted to hospital at 30 days following these procedures. When compared to overnight admission to hospital post-elective percutaneous structural heart condition closure, SDD yielded a cost saving of AUD 5999 per case. Conclusion: SDD following elective percutaneous closure of ASD and PFO was demonstrated to be a safe and effective strategy for managing patients. With more widespread use, it can lead to significant cost savings for hospitals without compromising patient care.

Sign in / Sign up

Export Citation Format

Share Document